Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Shenzhen Neptunus Interlong Bio-Technique Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Shenzhen Neptunus Interlong Bio-Technique Co FCF Yield % Related Terms
Shenzhen Neptunus Interlong Bio-Technique Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co FCF Yield % Chart
Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co FCF Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a FCF Yield % of 58.64 as of Sep. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. This is 666% above median its historical median of 7.66. According to the industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #11 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 1.1%.
Is Shenzhen Neptunus Interlong Bio-Technique Co's FCF Yield % too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current FCF Yield % of 58.64 is 666% above median its 10-year median of 7.66. The Drug Manufacturers industry median FCF Yield % is 0.82. Shenzhen Neptunus Interlong Bio-Technique Co's value of 58.64 is 7051.2% above this industry median. Based on the distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #11 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shenzhen Neptunus Interlong Bio-Technique Co has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Neptunus Interlong Bio-Technique Co's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #11 out of 1003 companies for FCF Yield %. This places Shenzhen Neptunus Interlong Bio-Technique Co in the top 1% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.82. Shenzhen Neptunus Interlong Bio-Technique Co's value of 58.64 is 7051.2% above this benchmark. While the company's 10-year median is 7.66 vs. the industry median of 0.82, Shenzhen Neptunus Interlong Bio-Technique Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.82, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Neptunus Interlong Bio-Technique Co's current FCF Yield % of 58.64 is 7051.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current FCF Yield % is 58.64, which is 666% above median its own 10-year median of 7.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.10 — trading 29.3% below its estimated fair value. The current FCF Yield % is 58.64, which is 666% above median its 10-year median of 7.66 and 7051.2% above the Drug Manufacturers industry median of 0.82. Shenzhen Neptunus Interlong Bio-Technique Co's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current FCF Yield % is 58.64 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co stock appears to be undervalued.
The current stock price of HK$0.10 is trading 29.3% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Shenzhen Neptunus Interlong Bio-Technique Co to be Modestly Undervalued.
Key valuation signals for HKSE:08329:
FCF Yield %: 58.64 (666% above median its 10-year median of 7.66)
GF Value™: HK$0.14 vs. price of HK$0.10 (29.3% below fair value)
Industry Position: 7051.2% above the Drug Manufacturers median (#11 of 1003)
No single metric tells the full story. See the HKSE:08329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
48GF Score
Get the complete analysis for HKSE:08329
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
